Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40TP5 | ISIN: US0008471031 | Ticker-Symbol:
NASDAQ
27.06.25 | 21:59
0,212 US-Dollar
-5,16 % -0,012
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ABPRO HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ABPRO HOLDINGS INC 5-Tage-Chart

Aktuelle News zur ABPRO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.06.Abpro Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
17.06.Abpro Holdings, Inc. - 8-K, Current Report 1
06.06.Abpro Holdings, Inc. - S-1/A, General form for registration of securities1
15.05.Abpro Holdings, Inc. - 10-Q, Quarterly Report1
27.04.Abpro Corporation: Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager158Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profileAbpro and Celltrion have a strategic partnership for worldwide development and commercialization...
► Artikel lesen
24.04.Abpro Holdings, Inc. - 8-K, Current Report1
15.04.Abpro Holdings, Inc. - 10-K, Annual Report1
ABPRO Aktie jetzt für 0€ handeln
15.04.Abpro Holdings, Inc. - 8-K, Current Report1
08.04.Abpro Holdings, Inc. - 8-K, Current Report1
01.04.Abpro Holdings, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4053
26.03.Abpro Holdings, Inc. - 8-K, Current Report1
25.03.Abpro Corporation: Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 20251
10.03.Abpro Corporation: Abpro Statement on the Departure of Former CEO Ian Chan187WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening...
► Artikel lesen
07.03.Abpro Holdings, Inc. - 8-K, Current Report-
21.02.Abpro Holdings, Inc. - 8-K, Current Report-
07.02.Abpro Holdings, Inc. - S-1/A, General form for registration of securities-
19.12.24Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology1.002CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over...
► Artikel lesen
13.11.24Abpro Announces Closing of Business Combination with Atlantic Coastal Acquisition Corp. II164Abpro Expected to Begin Trading on Nasdaq on Thursday, November 14, 2024, Under the Tickers "ABP" and "ABPWW" WOBURN, Mass. and NEW YORK, Nov. 13, 2024 /PRNewswire/...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1